Form 4 for TVTX Travere Therapeutics, Inc.
Accepted 2022-02-02 00:00:00 ET · period of report 2022-01-31 · accession 0001209191-22-006363 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-02-02 | 2022-01-31 | TVTX | Heerma Peter | Chief Commercial Off | A - Grant | $0.00 | +9,840 | 68.4K | +17% | $0 |
| D | 2022-02-02 | 2022-01-31 | TVTX | Heerma Peter | Chief Commercial Off | S - Sale | $27.40 | -1,125 | 67.3K | -2% | -$30.8K |
| DM | 2022-02-02 | 2022-01-31 | TVTX | Heerma Peter | Chief Commercial Off | A - Grant | $0.00 | +57.2K | 8,000 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-01-31 | A | A | 9,840 | $0.00 | 68,422 | D | — | — | |
| 2 | Common | Common Stock | 2022-01-31 | S | D | 1,125 | $27.40 | 67,297 | D | — | — | |
| 3 | Derivative | Employee stock option (right to buy) | 2022-01-31 | A | A | 39,360 | $0.00 | 39,360 | D | $27.50 · — to 2032-01-30 | 39,360 Common Stock | (F3) One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter. |
| 4 | Derivative | Performance-based restricted stock units | 2022-01-31 | A | A | 9,840 | $0.00 | 9,840 | D | — · — to — | 9,840 Common Stock | (F4) Each performance-based restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer. (F5) This grant will vest upon the achievement of specified clinical/regulatory and commercial milestones, provided, however, if either vesting event occurs before the date that is 12 months after the date of grant, then the portion of the award that would have vested upon such event will instead vest on the date that is 12 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2027 to the extent the specified performance based milestones are not achieved by such date. |
| 5 | Derivative | Performance-based restricted stock units | 2022-01-31 | A | A | 8,000 | $0.00 | 8,000 | D | — · — to — | 8,000 Common Stock | (F4) Each performance-based restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer. (F6) This grant will vest upon the achievement of specified clinical/regulatory milestones, provided, however, if the vesting events occur before the date that is 24 months after the date of grant, then the award will instead vest on the date that is 24 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2026 if the specified performance based milestones are not achieved by such date. |